🔍 This technology targets disease-associated proteins for degradation and could lead to the development of new therapeutic options.
🔍 Merck aims to leverage C4T’s expertise in targeted protein degradation to expand its oncology portfolio.
🔍 The collaboration will involve using C4T’s small molecule platform to develop antibody-based degraders.
🔍 This partnership highlights the increasing interest in targeted protein degradation as a potential therapeutic approach in oncology and other diseases.
Introduction:
In a recent partnership, Merck has collaborated with C4 Therapeutics (C4T) to develop targeted protein degraders using C4T’s degrader-antibody conjugate technology. This collaboration aims to bring new therapies to the market by selectively degrading disease-causing proteins.
- Merck has entered into a collaboration with C4 Therapeutics to develop degrader-antibody conjugates.
- C4T’s technology enables the selective degradation of disease-causing proteins, leading to potential therapeutic benefits.
- The collaboration will leverage Merck’s expertise in antibody development and C4T’s expertise in targeted protein degradation.
- This partnership aims to bring novel therapies to the market for the treatment of various diseases.
- The development of degrader-antibody conjugates has the potential to revolutionize the field of targeted therapy.
Conclusion:
The collaboration between Merck and C4 Therapeutics in developing degrader-antibody conjugates holds promise for the development of novel therapies that can selectively degrade disease-causing proteins. This partnership combines Merck’s expertise in antibody development with C4T’s innovative technology in targeted protein degradation. If successful, this collaboration could revolutionize the field of targeted therapy and provide new treatment options for various diseases.
